
Superpower peptides available for pre-order. Get first access.

Peptide science
How does VK2735 compare with tirzepatide?
VK2735 and tirzepatide both activate GLP-1 and GIP receptors. Compare trial data, side effects, and FDA status; no head-to-head trial has tested them.
Quick answer
VK2735 and tirzepatide both activate GLP-1 and GIP receptors. Tirzepatide is FDA-approved, with a 72-week Phase 3 trial (SURMOUNT-1, 2,539 adults) reporting 20.9% mean weight loss at 15 mg vs 3.1% with placebo. VK2735 is investigational, with 13-week Phase 2 data (VENTURE, 176 adults) showing 14.7% mean weight loss at 15 mg vs 1.7% with placebo. No trial has compared the two, and the different trial lengths mean the results cannot rank the two drugs.
- Published
- November 10, 2026
- Last updated
- November 10, 2026
How investigational VK2735 compares with approved tirzepatide
VK2735 and tirzepatide both activate receptors for two gut hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Tirzepatide, sold as Mounjaro and Zepbound, is FDA-approved1, while VK2735 is an investigational dual agonist and not FDA-approved. No trial has tested VK2735 against tirzepatide2, so which drug leads to more weight loss is unknown. For anyone comparing VK2735 vs tirzepatide, a few basic facts already set the two drugs apart.
VK2735 vs tirzepatide at a glance
| Feature | VK2735 | Tirzepatide |
| Developer | Viking Therapeutics3 | Eli Lilly and Company1 |
| FDA status | Investigational, not FDA-approved4 | Approved as Mounjaro for type 2 diabetes in 20225 and as Zepbound for weight management in 20236 |
| Receptors activated | GLP-1 and GIP7 | GIP and GLP-11 |
| Forms | Weekly injection; daily tablet in a 13-week Phase 2 trial8 (company-reported results only) | Weekly injection in pens or vials1 |
| Largest published trial | VENTURE: Phase 2, 176 adults, 13 weeks9 | SURMOUNT-1: Phase 3, 2,539 adults, 72 weeks10 |
| Mean weight loss at highest dose vs placebo | 14.7% vs 1.7% at 15 mg, 13 weeks7 | 20.9% vs 3.1% at 15 mg, 72 weeks10 |
| Phase 3 program | VANQUISH-1 and VANQUISH-2, about 4,500 and 1,000 adults, 78 weeks, completion expected in 20273; oral SUNRISE Phase 3 registered, not yet recruiting11 | SURMOUNT-1 completed and published |
Both drugs work through the same receptor pair.
VK2735 and tirzepatide target the same two receptors
VK2735 and tirzepatide are dual agonists, single molecules that activate both the GLP-1 and GIP receptors7. GLP-1 boosts insulin release after meals, slows stomach emptying, and curbs food intake12.
Tirzepatide was designed to test whether adding GIP activity13 improves on GLP-1-only drugs. In mice, rats, and musk shrews, activating the GIP receptor eased nausea-like behavior and vomiting from GLP-1 drugs14. In people, the GIP receptor remains a proposed target for easing nausea15. Drugs pairing GLP-1 activity with either GIP activation or GIP blocking have produced similar weight loss16, a puzzle researchers still debate.
VK2735 and tirzepatide are still different molecules. Tirzepatide engages the GIP receptor more strongly17 than the GLP-1 receptor at clinical doses. VK2735 carries a half-life-extending side chain7, but its receptor-binding figures come only from unpublished company data.
Whether shared biology yields similar results is a question for trial data.
Published VK2735 results span 13 weeks, tirzepatide's 72
VK2735 and tirzepatide weight-loss results come from trials of very different lengths, so they cannot be set side by side.
VENTURE, a 13-week Phase 2 trial, enrolled 176 adults with obesity, or overweight plus a weight-related condition. Weekly VK2735 at 2.5 mg to 15 mg lowered mean body weight by 9.1% to 14.7%, vs 1.7% with placebo7. Weight loss showed no sign of a plateau by week 137.
SURMOUNT-1, a 72-week Phase 3 trial, enrolled 2,539 adults meeting similar weight criteria. Weekly tirzepatide at 5 mg, 10 mg, and 15 mg lowered mean weight by 15%, 19.5%, and 20.9%, vs 3.1% with placebo10. The SURMOUNT-1 figures count every randomized participant, whether or not they stayed on treatment.
SURMOUNT-4 started 783 similar adults on tirzepatide at 10 mg or 15 mg. The 670 who finished the 36-week lead-in lost a mean 20.9% over 36 weeks18, a figure that leaves out those who stopped early. Over the next 52 weeks, weight rose 14% on placebo but fell 5.5%18 with continued tirzepatide. All three trials excluded people with diabetes, so the results do not extend to type 2 diabetes.
Phase 2 trials are too small to prove benefit. Phase 3 trials, built for that, enroll 300 to 3,000 people19 for one to four years. This comparison is for scientific context only. VK2735 and tirzepatide have fundamentally different regulatory statuses and evidence bases. Cross-trial comparisons are liable to bias20, so the data cannot rank the two drugs.
The same short-versus-long gap shapes what each drug's side-effect record can show.
VK2735 and tirzepatide side effects are mostly digestive
The most common side effects of VK2735 and tirzepatide are digestive, led by nausea, vomiting, diarrhea, and constipation. The same four effects top VK2735's 13-week trial safety data7 and tirzepatide's list of common reactions1.
SURMOUNT-1's digestive effects were mostly mild to moderate and came mainly during dose increases10. In VENTURE, VK2735's digestive effects eased once dosing reached a steady level7.
The trials used unmatched measures, so their side-effect rates cannot be compared directly. Ongoing Phase 3 trials will add longer-term data on VK2735's side effects before any approval decision.
Tirzepatide is approved, while VK2735 remains in trials
Tirzepatide is an FDA-approved prescription drug for weight management6, while VK2735 is investigational and not FDA-approved. VK2735's Phase 3 VANQUISH trials of weekly injections are expected to finish in 20273.
Until Phase 3 results appear, published trials are the best guide to how these dual-agonist peptides compare.
Where can I learn about peptides?
Tirzepatide's Phase 3 results are published, while VK2735's larger trials are still running, so the comparison will keep changing. Superpower’s peptide library follows approved and investigational dual-agonist drugs as findings appear. A team of health journalists and licensed clinicians writes and fact-checks each guide.
To see how incretin-based peptides like these bind and switch on hormone receptors, start with the science behind peptides.
IMPORTANT SAFETY INFORMATION
Tirzepatide is a prescription medication. Its FDA-approved labeling (Mounjaro, Zepbound) carries a boxed warning for risk of thyroid C-cell tumors; tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tirzepatide is not recommended during pregnancy. Serious adverse events reported include pancreatitis, gallbladder disease, acute kidney injury, and severe gastrointestinal reactions. Common adverse events include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and injection-site reactions.
Compounded tirzepatide is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness, or quality. A patient-specific prescription is required. Tirzepatide Rx is not available in all 50 states.
VK2735 is an investigational drug that is not FDA-approved for any use. It is not available by prescription, and access is limited to clinical trial enrollment. Nausea, vomiting, diarrhea, and constipation were the most common side effects in its published Phase 2 trial, and long-term safety data have not been published.
This article is for general information and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any prescription medication.
Full FDA-approved prescribing information for tirzepatide is available on DailyMed21.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health facilitates access to compounded tirzepatide through licensed healthcare providers and compounding pharmacy partners. Compounded tirzepatide is NOT equivalent to the branded products (Mounjaro or Zepbound). Superpower does not sell, prescribe, or facilitate access to any branded version of tirzepatide, or to VK2735. Compounded tirzepatide is a prescription medication available only by prescription. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.